Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors

Annals of Oncology

Volumn 11, Issue 4, 2000, Pages 385-391

  Van Triest, B ^a   Pinedo, H M ^a   Giaccone, G ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Antifolates; Apoptosis; DNA repair; p53; Thymidylate synthase

Indexed keywords

FLOXURIDINE; FLUOROURACIL; METESIND GLUCURONATE; NOLATREXED; PEMETREXED; PLEVITREXED; PROTEIN P53; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA REPAIR; DRUG DESIGN; FLUOROURACIL; FOLIC ACID ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; NEOPLASMS; PROGNOSIS; THYMIDYLATE SYNTHASE;

EID: 0034114654     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008351221345     Document Type: Review

References (62)

1. Radparvar S, Houghton PJ, Houghton JA. Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys 1988; 260: 342-50.
2. Eriksson S, Arner E, Spasokoukotskaja T et al. Properties and levels of deoxy-nucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 1994; 34: 13-25.
3. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer agents. Ann Oncol 1995; 6: 871-81.
4. Peters GJ, Jansen G. Resistance to antimetabolites. In Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology (Chapter 28). New York: Marcel Dekker 1996; 543-85.
5. Jackson RC. A kinetic model of regulation of the deoxyribonucleoside triphosphate pool composition. Pharmacol Ther 1984; 26: 279-301.
6. Mandel HG. The target cell determinants of the antitumor actions of 5-FU: Does FU incorporation into RNA play a role. Cancer Treat Rep 1981; 65: 63-71.
7. Wurzer JC, Tallarida RJ, Sirover MA. New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther 1994; 269: 39-43.
8. Walsh MJ, Shue G, Spidoni K, Kapoor A. E2F-1 and a cyclin-like DNA repair enzyme, uracil-DNA glycosylase, provide evidence for an autoregulatory mechanism for transcription. J Biol Chem 1995; 270: 5289-98.
9. Muller-Weeks SJ, Caradonna S. Specific association of cyclin-like uracil-DNA glycosylase with proliferation cell nuclear antigen. Exp Cell Res 1996; 226: 346-55.
10. Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 1993; 268: 15142-9.
11. Washtein WL. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol Pharmacol 1984; 25: 171-77.
12. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Resc 1992; 52: 2017-24.
13. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834-40.
14. Chu E, Koeller DM, Johnston PG et al. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993; 43: 527-33.
15. Chu E, Koeller DM, Casey JL et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1990; 90: 517-21.
16. Chu E, Koeller DM, Morrison PF et al. The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. J Biol Chem 1994; 269: 20289-93.
17. Chu E, Allegra CJ. The role of thymidylate synthase as an RNA binding protein. Bioessays 1996; 18: 191-8.
18. Yin M-B, Rustum YM. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: Relevance to cell growth inhibition. Cancer Comm 1991; 3: 45-51.
19. Yin M-B, Guimaraes MA, Zhang ZG et al. Time dependence of DNA lesions and growth inhibition of ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res 1992; 52: 5900-5.
20. Panadero A, Yin M-B, Voigt W, Rustum YM. Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncol Res 1995; 7: 73-81.
21. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridinde-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991; 51: 2346-52.
22. Ayusawa D, Shimizu K, Koyama H et al. Accumulation of DNA strand breaks during thymineless death in thymidylate synthase-negative mutants of mouse FM3A cells. J Biol Chem 1983; 258: 12448-54.
23. Yoshioka A, Tanaka S, Hiraoka O et al. Deoxyribonucleoside triphosphate imbalance. J Biol Chem 1987; 262: 8235-41.
24. Lönn U, Lönn S. DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines. Cancer Res 1986; 46: 3866-70.
25. Houghton JA, Morton CL, Adkins DA, Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-α2a in colon carcinoma cells. Cancer Res 1993; 53: 4243-50.
26. Van der Wilt CL, Smid K, Aherne GW et al. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 1997; 33: 471-8.
27. Houghton JA, Tillman DM, Harwood FG. Ratio of 2′-deoxyadenosin-5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1995; 1: 723-30.
28. Houghton JA, Harwood FG, Houghton PJ. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res 1994; 54: 4967-73.
29. Matsui S-I, Arredondo MA, Wrzosek C, Rustum YM. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res 1996; 56: 4715-23.
30. Lonn U, Lonn S. Increased growth inhibition and DNA lesions in human colon adenocarcinoma cells treated with methotrexate or 5-fluoro-deoxyuridine followed by calmodulin inhibitors. Cancer Res 1993; 48: 3319-23.
31. Canman CE, Lawrence TS, Shewach DS et al. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyruridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 1993; 53: 5210-24.
32. Canman CE, Radany EH, Parsels LA et al. Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. Cancer Res 1994; 54: 2296-8.
33. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6.
34. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: Implications for cancer. Cancer Metas Rev 1995; 14: 3-15.
35. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. Bioessays 1995; 17: 501-8.
36. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
37. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
38. Tishler RB, Stuart K, Calderwood C et al. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53: 2212-6.
39. Harwood FG, Frazier MW, Krajewski S, Reed JC, Houghton JA. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene 1996; 12: 2057-67.
40. Houghton JA, Harwood FG, Gibson AA, Tillman DM. The FAS signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin Cancer Res 1997; 3: 2205-9.
41. Tamura T, Aoyama N, Saya H et al. Induction of FAS-mediated apoptosis in p55-transfected human colon carcinoma cells. Oncogene 1995; 11: 1939-46.
42. Yin M-B, Voigt W, Panadero A et al. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol Pharmacol 1997; 51: 630-6.
43. Li W, Fan J, Hochhauser D, Banerjee D et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995; 92: 10436-40.
44. Peters GJ, VanTriest B, Backus HHJ et al. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor Tomudex. Eur J Cancer 2000 (in press).
45. Backus HHJ, Wouters D, Kuiper CM et al. Induction of apoptosis in colon cancer cell lines by the thymidylate synthase (TS) inhibitors, 5-fluorouracil (5-FU), AG337 (AG) and LY231514 (LY) is dependent on the p53 and probable the BCL-2 status. Proc AACR 1998; 38: 1215.
46. Chu E, Takechi T, Jones KL et al. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biology 1995; 15: 179-85.
47. Chu E, Copur S, Jones KL et al. Thymidylate synthase regulates the translation of p53 mRNA. Proc Am Ass Cancer Res 1995; 36: 3355.
48. Lee Y, Johnson LF, Chang LS. Chen Y. Inhibition of mouse thymidylate synthase promoter activity wild-type p53 tumor suppressor protein. Exp Cell Res 1997; 234: 270-6.
49. Kroemer G. The proto-oncogene BCL-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-20.
50. Korsmeyer SJ. Regulators of cell death. TIG 1995; 11: 101-5.
51. Fisher TC, Milner AE. Gregory CD et al. BCL-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993; 53: 3321-6.
52. Pritchard M, Watson AJM, Potten CS et al. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997; 94: 1795-9.
53. Martin DS, Stolfi RL, Sawyer RC et al. High-dose 5-fluorouracil with delayed uridine 'rescue'. Cancer Res 1982; 42: 3964-70.
54. Peters GJ, Van Dijk J, Laurensse E et al. In vitro biochemical and in vivo biological studies of uridine 'rescue' of 5-fluorouracil. Br J Cancer 1988; 57: 259-65.
55. Brown JM, Wouters BG. Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
56. Nita ME, Nagawa H, Tominaga O et al. 5-fluorouracil induces apoptosis in human colon cancer cell lines with modulation of BCL-2 family proteins. Br J Cancer 1998; 78: 986-92.
57. Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998; 4: 1243-50.
58. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase (TS) expression in untreated stage II colon cancer: Association with recurrence, survival and tumor site. Clin Cancer Res 1998; 4: 1227-34.
59. Elwell Y-P, Chang M, Leichman CG et al. p53, p21 and thymidylate synthase (TS) protein expression: Associations with recurrence in stage II and III rectal cancer. Proc Am Assoc Clin Oncol 1997; 16: 915.
60. Ward SA, Joel SP, Papamichael D et al. Thymidylate (TS) and p53 protein expression in patients with rectal cancer treated with preoperative 5-fluorouracil (5-FU) based chemo-radiotherapy (CRT). Proc Am Assoc Clin Oncol 1998; 17: 1040.
61. Seitz JF, Monges G, Milan C et al. Thymidylate synthase (TS) and p53 expression predict for early event-free survival (EFS) but not adjuvant chemotherapy efficacy in patients with colonic carcinoma (CC). Proc Am Assoc Clin Oncol 1998; 17: 1082.
62. Aschele C, Casazza S, Debernardis D et al. Lack of correlation between p53 overexpression and response to FUra-based chemotherapy in advanced colorectal cancer patients. Proc Am Assoc Clin Oncol 1997; 16: 916.